Orum raises $8M in series A

Antibody company Orum Therapeutics Inc. (Daejeon, South Korea) raised $8 million in a series A round. Investors included InterVest, KB Investment/Solidus Investment and LB Investment. InterVest's Yeo Jung Moon will join Orum's board.

The company's cell-penetrating antibody platform is designed to help biologics escape intracellular degradation, enabling them to inhibit cytosolic proteins such as Ras that are hard to target with small molecules (see BioCentury Innovations, Jan. 4)...